Erratum: SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro (Oncol Rep (2014) 32 (2533‑2540) DOI: 10.3892/or.2014.3539);SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro

Oncology Reports

Volumn 32, Issue 6, 2014, Pages 2533-2540

  Chen, Feifei ^a   Lu, Zheng ^a   Deng, Junpeng ^a   Han, Xuechao ^a   Bai, Jin ^a   Liu, Qinghua ^a   Xi, Yaguang ^a,b   Zheng, Junnian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Angiogenesis; Invasion; Motility; Prostate cancer; SPAG9

Indexed keywords

GELATINASE A; GELATINASE B; ONCOPROTEIN; SPERM ASSOCIATED ANTIGEN 9; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; VASCULOTROPIN; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SPAG9 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN; TIMP2 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN SECRETION; TUMOR INVASION; TUMOR VASCULARIZATION; UPREGULATION; CELL MOTION; CELL PROLIFERATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATIC NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84914695668     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2022.8314     Document Type: Erratum

References (34)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Ohlmann CH, Siemer S and Stöckle M: Resection of metastases from prostate cancer. Urologe A 51: 363-367, 2012 (In German).
3. Saleem M, Adhami VM, Zhong W, et al: A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 15: 217-227, 2006.
4. Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615-625, 2005.
5. Zendman AJ, Ruiter DJ and Van Muijen GN: Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 194: 272-288, 2003.
6. Garg M, Chaurasiya D, Rana R, et al: Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clin Cancer Res 13: 1421-1428, 2007.
7. Garg M, Kanojia D, Suri S and Suri A: Small interfering RNA-mediated downregulation of SPAG9 inhibits cervical tumor growth. Cancer 115: 5688-5699, 2009.
8. Kanojia D, Garg M, Gupta S, Gupta A and Suri A: Spermassociated antigen 9, a novel biomarker for early detection of breast cancer. Cancer Epidemiol Biomarkers Prev 18: 630-639, 2009.
9. Garg M, Kanojia D, Salhan S, et al: Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer 115: 2671-2683, 2009.
10. Chung MS, Lee SH, Lee DH and Chung BH: Evaluation of the 7th American Joint Committee on Cancer TNM staging system for prostate cancer in point of classification of bladder neck invasion. Jpn J Clin Oncol 43: 184-188, 2013.
11. Van der Kwast T, Bubendorf L, Mazerolles C, et al: Guidelines on processing and reporting of prostate biopsies: the 2013 update of the Pathology Committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Virchows Arch 463: 367-377, 2013.
12. Chen F, Wang M, Bai J, et al: Role of RUNX3 in suppressing metastasis and angiogenesis of human prostate cancer. PLoS One 9: e86917, 2014.
13. Mei PJ, Bai J, Liu H, et al: RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. J Cancer Res Clin Oncol 137: 1823-1830, 2011.
14. Chen F, Bai J, Li W, et al: RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma. PLoS One 8: e56241, 2013.
15. Jagadish N, Rana R, Selvi R, et al: Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting protein. Biochem J 389: 73-82, 2005.
16. Burks DJ, Carballada R, Moore HD and Saling PM: Interaction of a tyrosine kinase from human sperm with the zona pellucida at fertilization. Science 269: 83-86, 1995.
17. Luconi M, Krausz C, Forti G and Baldi E: Extracellular calcium negatively modulates tyrosine phosphorylation and tyrosine kinase activity during capacitation of human spermatozoa. Biol Reprod 55: 207-216, 1996.
18. Garg M, Kanojia D, Khosla A, et al: Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma. Cancer Res 68: 8240-8248, 2008.
19. Mocarska A, Staroslawska E, Iwonna ZC, et al: Diagnostic imaging of the prostate cancer. Pol Merkur Lekarski 33: 357-363, 2012 (In Polish).
20. Sfoungaristos S and Perimenis P: Clinical and pathological variables that predict changes in tumour grade after radical prostatectomy in patients with prostate cancer. Can Urol Assoc J 7: E93-E97, 2013.
21. Hynes RO: Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants - or both? Cell 113: 821-823, 2003.
22. Halbersztadt A, Halon A, Pajak J, Robaczynski J, Rabczynski J and St Gabrys M: The role of matrix metalloproteinases in tumor invasion and metastasis. Ginekol Pol 77: 63-71, 2006 (In Polish).
23. Zhang XY, Hong BF, Chen GF, Lu YL and Zhong M: Significance of MMP2 and MMP9 expression in prostate cancer. Zhonghua Nan Ke Xue 11: 359-361, 364, 2005 (In Chinese).
24. Jinga DC, Blidaru A, Condrea I, et al: MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med 10: 499-510, 2006.
25. Giannelli G, Erriquez R, Fransvea E, et al: Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer 109: 782-785, 2004.
26. Chen Y, Wei X, Guo C, et al: Runx3 suppresses gastric cancer metastasis through inactivation of MMP9 by upregulation of TIMP-1. Int J Cancer 129: 1586-1598, 2011.
27. Yi F, Ni W, Liu W, et al: SPAG9 is overexpressed in human astrocytoma and promotes cell proliferation and invasion. Tumour Biol 34: 2849-2855, 2013.
28. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
29. Ellis LM, Rosen L and Gordon MS: Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol 4: 1-10, 2006.
30. Shi Q, Le X, Abbruzzese JL, et al: Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61: 4143-4154, 2001.
31. Cao Y, Guangqi E, Wang E, et al: VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res 72: 3912-3918, 2012.
32. Xie K, Wei D, Shi Q and Huang S: Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 15: 297-324, 2004.
33. Pal S, Datta K and Mukhopadhyay D: Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 61: 6952-6957, 2001.
34. Guma M, Rius J, Duong-Polk KX, Haddad GG, Lindsey JD and Karin M: Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. Proc Natl Acad Sci USA 106: 8760-8765, 2009.